MTX难治性早期RA随机接受英夫利西单抗或SSZ+HCQ添加策略的14年死亡率比较
本研究基于Swefot随机开放标签试验,比较MTX难治性早期RA患者分别加用英夫利西单抗(n=128)或SSZ+HCQ(n=130)的长期死亡率。平均随访13年,两组死亡分别为13例和16例,死亡率风险比1.2(95%CI 0.6,2.5),差异无统计学意义。
要点
- 平均随访13年,英夫利西单抗组与SSZ+HCQ组死亡率无显著差异(HR 1.2,95%CI 0.6,2.5)
- 1年死亡率两组均为0.8%,10年死亡率分别为7.8%和7.7%
- 5年时约50%常规联合治疗组患者换用生物制剂,生物制剂组50%停用生物制剂
核心结论
- 在最长14年随访中,以英夫利西单抗起始添加策略与SSZ+HCQ添加策略相比,未观察到死亡率风险差异。
- 5年时(试验结束后3年),50%患者仍维持 assigned 治疗,提示DMARD联合治疗对50%患者是 adequate 策略。
研究设计与样本
- 数据来自Swefot试验:两臂、平行、随机、活性对照、开放标签设计,2002-2005年从瑞典15家风湿科门诊招募早期RA患者(症状持续时间<1年)。
- MTX治疗3-4个月未达低疾病活动度者随机加用英夫利西单抗(n=128)或SSZ+HCQ(n=130),随访至死亡、移居或随访结束,采用意向性治疗分析。
主要发现
- 平均随访13年,英夫利西单抗组死亡13例,SSZ+HCQ组死亡16例。
- 死亡率分别为8.8 vs 10.6例/1000人年;死亡风险比1.2(95%CI 0.6,2.5);P=0.62。
- 1年死亡率两组均为0.8%;5年死亡率英夫利西单抗组2.3% vs 常规联合组1.5%;10年死亡率分别为7.8%和7.7%。
关键数值与推荐
- MTX难治性早期RA(症状持续时间<1年)在MTX治疗3-4个月未达低疾病活动度后随机加用英夫利西单抗或SSZ+HCQ。
- 死亡风险比1.2(95%CI 0.6,2.5),P=0.62。
- 5年时约50%常规联合治疗组患者换用生物制剂,生物制剂组50%停用生物制剂DMARD。
临床怎么用
- 对于MTX难治性早期RA,起始加用英夫利西单抗或SSZ+HCQ的长期死亡率无明显差异,支持DMARD联合策略在部分患者中的适用性。
- 约半数患者5年后仍维持初始 assigned 治疗,提示常规联合治疗对50%患者足够。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare mortality risk over up to 14 years of follow-up in methotrexate-refractory patients with early RA randomized to a strategy starting with addition of infliximab vs addition of SSZ and HCQ. METHODS: Data was from the two-arm, parallel, randomized, active-controlled, open-label Swefot trial in which patients with early RA (symptom duration <1 y) were recruited from 15 rheumatology clinics in Sweden (2002-2005). Patients who did not achieve low disease activity after 3-4 months of MTX were randomized to addition of infliximab (n = 128) or SSZ and HCQ (n = 130). Participants were followed until death, emigration, or end of follow-up, whichever came first. Analyses were by intention-to-treat. RESULTS: Over an average follow-up of 13 years, there were 13 and 16 deaths, respectively [8.8 vs 10.6 deaths per 1000 person-years; mortality hazard ratio 1.2 (95% CI: 0.6, 2.5); P =0.62]. The 1-year mortality was 0.8% in both treatment arms, the 5-year mortality was 2.3% for the infliximab arm compared with 1.5% for the conventional combination treatment arm, while the 10-year mortality was 7.8% and 7.7%, respectively. After 5 years, ∼50% of patients in the conventional combination therapy arm had switched to biologic treatment, and 50% in the biologic arm had discontinued treatment with a biologic DMARD. CONCLUSION: No difference in mortality risk could be observed over up to 14 years of follow-up between treatment strategy groups. At 5 years (3 years after trial cessation), 50% of patients remained on their assigned therapy, reflecting that DMARD combination is an adequate treatment strategy in 50% of patients. TRIAL REGISTRATION: clinicaltrials.gov, identifier: NCT00764725.
引用
- Miller H, Wallman JK, Petersson IF, et al. Mortality over 14 years in MTX-refractory patients randomized to a strategy of addition of infliximab or sulfasalazine and hydroxychloroquine. Rheumatology (Oxford). 2021. PMID: 33179071. doi:10.1093/rheumatology/keaa553
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。